Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,189
datasets available to search
ShareScore release 0.9.0
Dataset results
2,189 results for “AML”
A Phase 1B Investigator Initiated Study of Safety and Tolerability of Dexamethasone (D) in Combination With Venetoclax-based Low-Intensity Therapy (LIT) in Treatment-Naïve Acute Myeloid Leukemia (AML)
ClinicalTrials.gov study NCT07014462. IPD Sharing: NO. Countries: 1. Publications: 0.
Treatment Patterns and Key Healthcare Resource Use in Acute Myeloid Leukemia (AML) With or Without FMS-like Tyrosine Kinase-3 (FLT3) Mutation Study Based on Retrospective Chart Review
ClinicalTrials.gov study NCT03047083. IPD Sharing: NO. Countries: 1. Publications: 0.
Dose Escalation of Clofarabine in Combination With Cytarabine and Idarubicin as Induction Therapy in High Risk AML
ClinicalTrials.gov study NCT01534702. IPD Sharing: Not stated. Countries: 1. Publications: 0.
STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders
ClinicalTrials.gov study NCT00858572. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Efficacy of Intermediate-Dose Cytarabine Induction Regimen in Adult AML
ClinicalTrials.gov study NCT03021330. IPD Sharing: NO. Countries: 1. Publications: 0.
Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP)
ClinicalTrials.gov study NCT02717884. IPD Sharing: NO. Countries: 1. Publications: 0.
MLN 9708 in Induction and Consolidation for Adults With AML >= 60 Years of Age
ClinicalTrials.gov study NCT02582359. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment
ClinicalTrials.gov study NCT06696183. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Study on the Efficacy and Safety of MA-BUCY2 Conditioning in High-risk AML Patients Underwent Haplo-HSCT
ClinicalTrials.gov study NCT05814731. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Safety, Tolerability and PK of AZD1152 in Patients With Relapsed Acute Myeloid Leukaemia (AML)
ClinicalTrials.gov study NCT00530699. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Chidamide Prevents Recurrence of High-risk AML After Allo-HSCT
ClinicalTrials.gov study NCT05682755. IPD Sharing: YES. Countries: 1. Publications: 0.
Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic Syndromes
ClinicalTrials.gov study NCT00451997. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML
ClinicalTrials.gov study NCT06221683. IPD Sharing: NO. Countries: 1. Publications: 0.
NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS
ClinicalTrials.gov study NCT04623944. IPD Sharing: NO. Countries: 1. Publications: 0.
RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma
ClinicalTrials.gov study NCT00081874. IPD Sharing: Not stated. Countries: 1. Publications: 0.
High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)
ClinicalTrials.gov study NCT07177079. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Azacitidine in Combination With Low Dose Intensity Venetoclax in Patients With AML Incl. Explorative AML Profiling
ClinicalTrials.gov study NCT05431257. IPD Sharing: NO. Countries: 1. Publications: 0.
A Study of (Interleukin-12) IL-12 in Patients With Acute Myelogenous Leukemia (AML)
ClinicalTrials.gov study NCT02483312. IPD Sharing: Not stated. Countries: 1. Publications: 0.
The Efficacy and Safety Assessment of Allogeneic γδ T Cells in Patients With MRD-positive AML After Allo-HSCT
ClinicalTrials.gov study NCT07126782. IPD Sharing: NO. Countries: 1. Publications: 0.
Epacadostat, Cladribine and Cytarabine (ECC) in AML
ClinicalTrials.gov study NCT03491579. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.